Stock·NYSE·Healthcare
Agilent Technologies (A)
- Market cap
- $48.77B
- P/E
- 34.63
- Dividend yield
- 0.59%
- Street target
- $180.00median of 22 analysts
- 52-week range
- $108.35 $177.47
The short version
Where A stands today, in four lines, and what CleaRank Financial AI makes of it.
A at a glance
Agilent Technologies (A): Buy, 77/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($158.89 and $134.50).
- Earnings A beat estimates in 6 of its last 8 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $3.8M and made no open-market purchases over the last 18 months.
- Valuation P/E of 34.6 against 31.9 for the Healthcare sector: broadly in line with peers (+9%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Agilent Technologies (A) Buy, with a model score of 77/100.
The trend lifts the score most: the price is 28.60% above its 200-day average and 8.86% above its 50-day average, and the 50-day average is 18.14% above the 200-day. Valuation holds it back most: the P/S of 6.71 is 97.4% above the sector median. The 50-day average stands at $158.89 and the 200-day at $134.50. Over the past year the price rose 22.59%.
Only on CleaRank
Figures we compute ourselves from A's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $172.97 is 8.9% above the 50-day simple moving average of $158.89.Price above its 200-day average ›
The price is 28.6% above the 200-day simple moving average of $134.50.50-day average above the 200-day ›
The 50-day average ($158.89) is 18.1% above the 200-day average ($134.50), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 93% of its 52-week range, between $108.35 and $177.47.
A share price
Pick a period: each tab shows how far A has moved over it, to the last close.
Today's trading
Where A sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 34.63 is 8.5% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 6.71 is 97.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.4B on revenue of $7.4B, a net margin of 19.5%.Beat estimates in most recent reports ›
A beat the EPS estimate in 6 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 0.59%, or $1.02 a share a year.
Key statistics
The headline figures for A.
As of October 17, 2026, A trades at $172.97, with a market value of $48.77B, a P/E ratio of 34.63 and a dividend yield of 0.59%.
What the numbers say
CleaRank Financial AI's reading of A's valuation, growth and risks.
A trades on 34.63 times earnings, compared with a Healthcare sector median of 31.9. That leaves the P/E 8.5% above the median, and the P/E is broadly in line with peers. Measured against sales, the P/S of 6.71 is 97.4% above the sector median of 3.4. A carries a market value of $48.8B.
Revenue grew 8.10% in the latest year. A net margin of 19.53% and an operating margin of 25.56% show how much of each sale reaches profit, and the return on equity of 20.97% sits above the sector median of 7.3%. Debt-to-equity stands at 0.56, and the trailing dividend yield of 0.59% works out to $1.02 a share a year.
A beat expectations in the August 26, 2026 report by 8.72%, reporting $1.62 a share against an estimate of $1.49. In the next session the shares climbed 1.68%.
A has beaten estimates in 6 of the last 8 reports, yet a beat has not reliably lifted the shares: the stock fell the next session after 2 of those 6 beats. For this fiscal year, analysts average an EPS estimate of $6.20, an expected change of 10.9%. Next year's average estimate is $6.76, a projected change of 8.9%.
Daily swings are the main risk to plan around, since A has moved 1.84% on an average session. Insider sales over the last 18 months totalled $3.8M, and there were no open-market purchases. Insider selling is usually read with care: sales are often planned in advance or made to cover tax on vesting shares, which makes them a weaker signal than purchases.
A against the Healthcare sector
How A compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (9% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 6, 2025, A has gained 64.4% against a gain of 31.6% for XLV.
Performance against XLV
A and the Healthcare sector fund over the same days.
Revenue and earnings
How much A sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.7% in FY2025 to $6.9B, from $6.5B a year earlier.
Profit margin: The net margin was 18.8% in FY2025, down from 19.8% the year before.
Profitable: A earned $1.3B in FY2025.
Earnings reality check
Did A beat what analysts expected, and how did the stock react?
Earnings record: A beat the analyst estimate in 6 of the last 8 quarters.
Market reaction: The stock fell in the first session after 2 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 26, 2026after close | $1.49 | $1.62 | +8.72% | +1.68% | -2.38% |
| May 27, 2026after close | $1.41 | $1.49 | +5.67% | +16.87% | +18.61% |
| Feb 25, 2026after close | $1.37 | $1.36 | -0.73% | -3.01% | -3.35% |
| Nov 24, 2025after close | $1.58 | $1.59 | +0.63% | +2.34% | -3.12% |
| Aug 27, 2025after close | $1.37 | $1.37 | +0.00% | +5.28% | +8.25% |
| May 28, 2025after close | $1.26 | $1.31 | +3.97% | +2.16% | +3.66% |
| Feb 26, 2025after close | $1.27 | $1.31 | +3.15% | -5.50% | -5.92% |
| Nov 25, 2024after close | $1.41 | $1.46 | +3.55% | -0.09% | +3.56% |
As of October 17, 2026, A has beaten the analyst EPS estimate in 6 of its last 8 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on August 26, 2026, came in 8.72% above the estimate and the stock moved +1.68% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 62.3, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 62.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of A
The score, the reasoning behind it, and what could move the price next.
Agilent Technologies (A) is in an uptrend. The price of $172.97 sits 28.60% above its 200-day average of $134.50 and 8.86% above its 50-day average of $158.89. The stock is at 93% of its 52-week range, meaning the price is 2.54% below the 52-week high of $177.47. The 50-day average is itself 18.14% above the 200-day average.
On momentum, the 14-day RSI reads 62.3, in the bullish zone, below the overbought line, with the MACD line positive. Every period on the chart shows a gain, with the price up 31.58% over the past three months, 41.93% over the past six months and 22.59% over the past year. The price fell 1.47% in the last session on volume 40.3% above its average.
Earnings beat ›
The August 26, 2026 report beat the EPS estimate by 8.72%, and the share price rose 1.68% in the first session after it.
Source: Earnings report, August 26, 2026
Rating reaffirmed ›
Barclays kept its Overweight rating on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- Keep an eye on the two closest levels: the 52-week high at $177.47 above the price, and the 20-day EMA at $168.57 below it.
- The 14-day RSI reads 62.3, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price rose 1.68% in the first session after the August 26, 2026 report. A has beaten estimates in 6 of the last 8 reports.
A's trend is up because the price holds above its 50-day and 200-day moving averages ($158.89 and $134.50), at $158.89 and $134.50. The 50-day is the first line to watch: a drop through it would be the first warning sign. Closer to the price, the 20-day EMA at $168.57 is the nearest support below it.
A has the 52-week high of $177.47 as its next level overhead. The RSI is in the bullish band, which backs the current direction without signalling an overstretched move.
Technical indicators
Momentum and trend for A, from its daily closes.
As of October 17, 2026, with A at $172.97, its 14-day RSI is 62.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $158.89 and its 200-day is $134.50.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What A moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, A's 1-year correlation of daily returns is +0.50 with S&P 500 (SPY), +0.42 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and +0.04 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
15 of 22 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $180.00 is 4.1% above the price.More buy ratings than three months ago ›
15 of 22 rate it a buy now, against 17 of 21 three months ago.
A Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Aug 28, 2026 | Wells Fargo | Maintains | Overweight |
| Aug 27, 2026 | Stifel | Maintains | Buy |
| Aug 27, 2026 | B of A Securities | Maintains | Buy |
| Aug 27, 2026 | Citigroup | Maintains | Buy |
| Aug 27, 2026 | Goldman Sachs | Maintains | Buy |
As of October 17, 2026, 22 Wall Street analysts cover A: 15 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $155.00 to $195.00, with a median of $180.00, 4.1% above the price of $172.97.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
A trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from A's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much A tends to move, against the market and on its own.
The long record
A's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.84% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 42.7%, from September 2021 to April 2025, regained by September 2026.Most 1-year holds ended higher ›
70% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $41,386, against $42,055 in the S&P 500 (SPY).
A Drawdowns & Recovery
As of October 17, 2026, A's worst peak-to-trough fall over the last 10 years with dividends reinvested was -42.7% (September 2021 to April 2025); it regained that peak by September 2026, 17 months after the low, and 70% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into A in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: A trailed the S&P 500 over this period: $41,386 against $42,055.
A $10,000 investment in A in October 2016 would be worth about $41,386 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to A, and which have not.
Strongest month, November: an average of +7.90%, up in 9 of 10 years.
Weakest month, February: an average of -3.79%, up in 4 of 10 years.
This month, October: has averaged +0.01%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, A's strongest calendar month has been November (average +7.90%, up in 9 of 10 years) and its weakest February (average -3.79%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in A, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in A today could grow to about $23,835 by 2036 in the base case, with a 90th-percentile outcome near $75,057 and a 10th-percentile outcome around $7,569. The simulation models price only; at today's 0.59% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
A Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $245 for A by 2030 in the base case, from $173 today (1.4x over 4 years). The 10th-percentile path ends near $119. These are outcomes of a Monte Carlo simulation run on A's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $131 | $189 | $271 | |
| 2028 | $123 | $206 | $344 | |
| 2029 | $120 | $224 | $421 | |
| 2030 | $119 | $245 | $506 | |
| 2031 | $119 | $267 | $601 |
Method: a lognormal simulation of A's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
A insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought A shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, A insiders reported 10 open-market sales worth $3.8M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Glenn S Boehnlein
Director
|
Grant | 817 | $120.0K |
| Sep 4, 2026 | Mikael Dolsten
Director
|
Sell | 634 | $96.0K |
| May 29, 2026 | Mikael Dolsten
Director
|
Sell | 1.6K | $216.7K |
| May 19, 2026 | Michael Steven Buckner
Officer
|
Grant | 8.9K | - |
| Mar 19, 2026 | Mala Anand
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Otis W Brawley
Director
|
Grant | 3.0K | $340.4K |
| Mar 19, 2026 | Judy Lynne Gawlik Brown
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Mikael Dolsten
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Boon Hwee Koh
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Daniel K Podolsky
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Sue H Rataj
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | George A Scangos
Director
|
Grant | 3.2K | $359.3K |
| Mar 19, 2026 | Pascal Soriot
Director
|
Grant | 2.2K | $241.2K |
| Mar 19, 2026 | Dow R Wilson
Director
|
Grant | 2.2K | $241.2K |
| Dec 1, 2025 | Mikael Dolsten
Director
|
Sell | 2.6K | $389.5K |
| Nov 26, 2025 | Rodney Gonsalves
Officer
|
Sell | 3.0K | $465.0K |
| Nov 26, 2025 | Rodney Gonsalves
Officer
|
Grant | 400 | $61.7K |
| Nov 18, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Sell | 911 | $130.5K |
| Nov 18, 2025 | Bret M Dimarco
Officer
|
Grant | 6.9K | - |
| Nov 18, 2025 | Adam Stewart Elinoff
Chief Financial Officer
|
Grant | 11.7K | - |
| Nov 18, 2025 | Rodney Gonsalves
Officer
|
Grant | 4.9K | - |
| Nov 18, 2025 | Meghan Henson
Officer
|
Grant | 5.4K | - |
| Nov 18, 2025 | Jonah Prevost Kirkwood
Officer
|
Grant | 7.5K | - |
| Nov 18, 2025 | Simon May
Officer
|
Grant | 6.8K | - |
| Nov 18, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Grant | 40.4K | - |
| Nov 18, 2025 | Angelica Riemann
Officer
|
Grant | 8.3K | - |
| Nov 18, 2025 | Jianmiao Mike Zhang
Officer
|
Grant | 6.6K | - |
| Nov 12, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Sell | 12.5K | $1.9M |
| Nov 12, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Option | 12.5K | $1.4M |
| Sep 2, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Sell | 2.0K | $249.8K |
| Aug 1, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Sell | 2.0K | $226.9K |
| Jul 16, 2025 | Rodney Gonsalves
Officer
|
Grant | 9.0K | $1.0M |
| Jul 1, 2025 | Padraig Mcdonnell
Chief Executive Officer
|
Sell | 1.5K | $177.1K |
| Jun 18, 2025 | Judy Lynne Gawlik Brown
Director
|
Sell | 7 | $904 |
| May 21, 2025 | Judy Lynne Gawlik Brown
Director
|
Grant | 1.7K | $182.6K |
| May 21, 2025 | Judy Lynne Gawlik Brown
Director
|
Grant | 1.7K | $182.6K |
| May 21, 2025 | Pascal Soriot
Director
|
Grant | 1.7K | $182.6K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.